Clinical Evaluation of miR-155 and miR-21 Alone and in Combination for Diagnosis of Acute Progressive Cerebral Infarction
Clinical Evaluation of miR-155 and miR-21 Alone and in Combination for Diagnosis of Acute Progressive Cerebral Infarction
Linyu Zhou, Hong Yu, Yang Wang, Jianbing Bai, Chuanyan Bao and Yongqing Dai*
ABSTRACT
The objective of this study was to clinical evaluate miR-155 and miR-21 alone and in combination for the diagnosis of acute progressive cerebral infarction (APCI). One hundred twenty-nine patients with acute cerebral infarction (ACI) were collected as observation objects and divided into an APCI group and no progression group according to the progress of the patients’ cerebral infarction, and 40 healthy people were selected as a control group. The levels of miR-155 and miR-21 in all subjects were determined by qRT-PCR. The miR-155 and miR-21serum levels in the APCI group and the progression-free group were higher than in control group, meanwhile those in the APCI group were higher than progression-free group (P<0.05). MLR analysis showed that miR-155 and miR-21 were influencing factors in APCI patients (P<0.05). ROC curve analysis showed that the AUC of miR-155 for APCI diagnosis was 0.869, the sensitivity was 86.13%, and the specificity was 81.75%.The AUC of miR-21 for APCI diagnosis was 0.815, the sensitivity was 83.49%, and the specificity was 78.43%; The AUC of the two combined for APCI diagnosis was 0.925, the sensitivity was 92.10%, and the specificity was 93.71%. It was concluded that the expression of miR-155 and miR-21 in the serum of APCI patients is significantly high, which are influencing factors in APCI patients. The combination of the two can be widely used in clinical practice.
To share on other social networks, click on any share button. What are these?
